A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

NCT01160211 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

369

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms, Breast

Interventions

DRUG: Lapatinib
DRUG: Trastuzumab
DRUG: Aromatase Inhibitor
DRUG: Lapatinib

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]